- Johnson & Johnson is buying biotech Firefly Bio for $1 billion to expand its cancer drug pipeline.
- Firefly's Firelink platform delivers protein-degrading drugs into cancer cells, targeting KRAS-mutant tumors long seen as "undruggable."
- The deal is expected to close later this year — a big bet on targeted treatments for hard-to-treat solid cancers.
The news, distilled into what matters.
Get the full experience in the app — topics, comments, and audio summaries.